FDA Requests Changes to Testosterone Therapy Labels
Federal health officials have requested changes to testosterone product labels, including language about age-related hypogonadism and prostate health. The June 18, 2026 announcement changes the regulatory discussion, but it does not remove the need to establish a diagnosis or review treatment risks.
What HHS and FDA Announced
HHS says FDA wants manufacturers to remove the limitation stating that safety and effectiveness have not been established for age-related hypogonadism. The requested revisions also address prostate cancer and benign prostatic hyperplasia. The announcement describes requested changes to prescribing information, rather than a recommendation that all older men should receive testosterone.
The prostate proposals would narrow the cancer contraindication to metastatic disease and revise wording about worsening urinary symptoms from an enlarged prostate. HHS also acknowledges uncertainty about long-term prostate cancer outcomes and the limited evidence in men with severe urinary symptoms. It calls for continued assessment and monitoring.
A Label Update and a Treatment Decision Answer Different Questions
Prescribing information defines a product's approved uses, contraindications, warnings, and other instructions. A clinician still needs to decide whether a particular patient has a condition that warrants treatment. Removing restrictive wording does not identify the cause of fatigue, reduced desire, or difficulty maintaining an erection.
FDA's testosterone information page continues to describe approved treatment in men with low testosterone and an associated medical condition. It also records the June labeling request. Those two points should remain separate when reading the news: a request to revise language does not make every possible use appropriate, and it does not mean that each manufacturer's label has already completed the same revision process.
The Cardiovascular Study Behind Part of the Change
The TRAVERSE trial supplies much of the evidence behind the revised safety discussion. Investigators randomized 5,246 men aged 45-80 who had symptoms, two low fasting testosterone measurements, and existing cardiovascular disease or a high risk of it. The trial compared testosterone gel with placebo.
The main cardiovascular endpoint occurred in 7.0% of the testosterone group and 7.3% of the placebo group. The trial met its noninferiority criterion for that endpoint. Researchers nevertheless reported higher incidences of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group. A result about one defined cardiovascular endpoint cannot establish that treatment has no adverse effects.
Blood Pressure Still Needs a Separate Review
In February 2025, FDA announced a separate class-wide labeling action after reviewing TRAVERSE and ambulatory blood pressure studies. The agency removed boxed-warning language about increased adverse cardiovascular outcomes and required blood pressure information for testosterone products. The change reflected two different bodies of evidence, rather than a declaration that monitoring no longer matters.
For a patient, the practical question is which checks apply to the product under consideration. Ask how the clinician will review blood pressure, blood counts, symptoms, and prostate-related findings. A favorable result in a supervised trial does not describe treatment without follow-up or the use of doses intended to push hormone levels beyond the treatment target.
Symptoms and Laboratory Results Still Need to Agree
The Endocrine Society's clinical guideline recommends diagnosing hypogonadism when symptoms or signs accompany consistently low testosterone measurements. It recommends confirming a low result with another morning fasting test. Low energy alone cannot settle the diagnosis, and a single result can lead to the wrong interpretation.
Before an appointment, gather previous laboratory reports with their collection times and reference ranges. List prescription medicines, supplements, sleep concerns, and your main reason for seeking treatment. Tell the clinician if you want children. The conversation should cover the diagnosis, expected symptom benefit, alternatives, and a plan for reviewing response.
Check Which Change a Headline Describes
The regulatory timeline matters. The large cardiovascular trial preceded the 2025 blood pressure and boxed-warning action; the June 2026 announcement addresses another set of requested label changes. Reading those events as one blanket safety decision loses distinctions that affect a consultation.
When you bring an article to an appointment, identify the announcement date and the product you want to discuss. Ask which prescribing information currently applies and whether your concern involves an approved use, a proposed wording change, or an individual decision that needs further assessment. That keeps the discussion tied to the actual medicine and clinical question.
Questions Worth Asking Before Starting
Ask which part of the new label discussion applies to your situation and which uncertainties remain. If you have previously received treatment for prostate cancer, bring your cancer history and PSA results rather than assuming the announcement settles your candidacy. If urinary symptoms trouble you, describe them before choosing a formulation.
The low testosterone section explains the consultation process. A visit should establish a reason for treatment and a way to judge whether it helps, rather than use a regulatory headline as a substitute for an individual assessment.

Comments